Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 9, 2012, Pages 2207-2212

  Leroy, Bertrand ^a   Uhart, Mathieu ^a   Maire, Pascal ^a,b   Bourguignon, Laurent ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

Geriatric; Minimum inhibitory concentrations; Pharmacodynamics; Renal impairment

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; OFLOXACIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; DEMOGRAPHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; GERIATRIC DISORDER; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; PLASMA;

EID: 84865357712     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks195     Document Type: Article

References (39)

1. Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther 1999; 21: 3-40; discussion 1-2.
2. Pickerill KE, Paladino JA, Schentag JJ. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy 2000; 20: 417-28.
3. Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31: 347-82.
4. Rossolini GM, Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect 2008; 14 Suppl 6: 2-8.
5. Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 2009; 12: 476-81.
6. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009; 64 Suppl 1: i3-10.
7. Ludwig E, Konkoly-Thege M, Kuti JL et al. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals. Int J Antimicrob Agents 2006; 28: 433-8.
8. Gillespie EL, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials: treatment optimisation. Expert Opin Drug Metab Toxicol 2005; 1: 351-61.
9. Schentag JJ, Goss TF. Quinolone pharmacokinetics in the elderly. Am J Med 1992; 92: 33S-7S.
10. Forrest A, Ballow CH, Nix DE et al. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993; 37: 1065-72.
11. Deguchi T, Nakane K, Yasuda M et al. Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis. Int J Antimicrob Agents 2010; 35: 573-7.
12. Zhang J, Xu J-F, Liu Y-B et al. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. J Infect Chemother 2009; 15: 293-300.
13. Rademaker CM, Jones RW, Notarianni LJ et al. Pharmacokinetics of a single dose of ofloxacin in healthy elderly subjects using noncompartmental and compartmental models. Pharm Weekbl Sci 1989; 11: 224-8.
14. Fillastre JP, Leroy A, Humbert G. Ofloxacin pharmacokinetics in renal failure. Antimicrob Agents Chemother 1987; 31: 156-60.
15. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-20.
16. EUCAST. Ciprofloxacin: Rationale for the EUCAST Clinical Breakpoints, Version 1.9. 2007. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_ files/Rationale_documents/Ciprofloxacin_rationale_1.9.pdf (20 March 2012, date last accessed).
17. EUCAST. Levofloxacin: Rationale for the EUCAST Clinical Breakpoints, Version 1.5. 2007. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Levofloxacin_rationale_1.5.pdf (20 March 2012, date last accessed).
18. EUCAST. Ofloxacin: Rationale for the EUCAST Clinical Breakpoints, Version 1.4. 2007. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Ofloxacin_rationale_1.4.pdf (20 March 2012, date last accessed).
19. AFSSAPS. Antibiotic therapy in general and current practices in upper respiratory tract infections in adults and children. Recommendations. Med Mal Infect 2005; 35: 566-77.
20. Blondeau JM, Hansen G, Metzler K et al. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother 2004; 16 Suppl 3: 1-19.
21. Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81.
22. Madaras-Kelly KJ, Ostergaard BE, Hovde LB et al. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996; 40: 627-32.
23. Lister PD, Sanders CC. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1999; 43: 1118-23.
24. Drusano GL, Preston SL, Fowler C et al. Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189: 1590-7.
25. Fantin B, Leggett J, Ebert S et al. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother 1991; 35: 1413-22.
26. Drusano GL, Johnson DE, Rosen M et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 483-90.
27. Mouton JW, van Ogtrop ML, Andes D et al. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 1999; 43: 2473-8.
28. Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003; 17: 529-43.
29. Fung-Tomc JC, Minassian B, Kolek B et al. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother 2000; 44: 3351-6.
30. Shams WE, Evans ME. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections. Drugs 2005; 65: 949-91.
31. Zelenitsky S, Ariano R, Harding G et al. Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations. Antimicrob Agents Chemother 2005; 49: 4009-14.
32. Burgess DS, Hall RG II. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. Clin Ther 2007; 29: 1421-7.
33. Koomanachai P, Bulik CC, Kuti JL et al. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010; 32: 766-79.
34. Montgomery MJ, Beringer PM, Aminimanizani A et al. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45: 3468-73.
35. Kashida Y, Kato M. Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds. Antimicrob Agents Chemother 1997; 41: 2389-93.
36. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 2002; 127: 269-77.
37. Bertino J Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22: 798-817; discussion 797.
38. Nicolle LE. Quinolones in the aged. Drugs 1999; 58 Suppl 2: 49-51.
39. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001; Suppl 1: S39-46.